Rezolute Inc. Common Stock (NV) (RZLT)
RZLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$4.61
-5.34% on the day
Market cap
$445.9M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RZLT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001509261 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-12-05 |
| Latest annual report | 10-K | 2026-09-24 |
| Latest quarterly / interim | 10-Q | 2026-05-12 |
| Latest current report FORM 8-K | 8-K | 2026-10-05 |
| Latest proxy | PRE 14A | 2026-10-07 |
Source: SEC EDGAR submissions feed, 750 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -2.1% |
| 1 month | +3.4% |
| 3 months | -1.8% |
| Year to date | +81.8% |
| 1 year | -46.8% |
| From 52-week high | -60.8% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARVN | Arvinas Inc. | $6.84 | -8.19% | $447.2M |
| KMDA | Kamada Ltd. | $7.69 | -1.91% | $443.8M |
| NGNE | Neurogene Inc. Common Stock | $21.56 | -11.78% | $431.4M |
| PRTA | Prothena Corporation plc | $8.36 | -0.83% | $429.2M |
| OVID | Ovid Therapeutics Inc. | $2.19 | -9.13% | $427.7M |
| OCS | Oculis Holding AG | $7.62 | -3.30% | $469.3M |
| DMAC | DiaMedica Therapeutics Inc. | $7.82 | -4.63% | $421.7M |
| ALT | Altimmune Inc. | $2.43 | -5.08% | $472.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier